CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC 50 s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity.
Storage Temp
Store at -20°C
Shipped In
Ice chest + Ice pads
Product Description
CLK-IN-T3 is a high potent, selective, and stable CDC-like kinase (CLK) inhibitor with IC 50 s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity
In Vitro
CLK-IN-T3 inhibits DYRK1A (IC 50 =260 nM) and DYRK1B (IC 50 =230 nM). CLK-IN-T3 (0.1-10.0 µM; 24 hours) results in mild cell cycle arrest at the G2/M boundary with long-duration (24 h). CLK-IN-T3 (0.5-1.0 µM; 6 hours) decreases phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cycle AnalysisCell Line: HCT-116 cells Concentration: 0.1, 0.5, 1.0, 5.0, 10.0 µM Incubation Time: 24 hours Result: Resulted in mild cell cycle arrest at the G2/M boundary with long-duration (24 h). Western Blot AnalysisCell Line: HCT-116 cells Concentration: 0.5, 1.0 μM Incubation Time: 6 hours Result: Decreased phosphorylation of CLK-targeted SR proteins and CLK proteins increased slightly.
